University of Pittsburgh Brain Health Initiative
Prevalence of Brain Health Versus Neurodegeneration in Former Professional Football Players
About This Trial
This project will define the prevalence of brain health (i.e., normal cognitive, neuromotor, behavioral function) in living professional football retirees and group-matched controls through a comprehensive assessment of clinical, neuroimaging, and biomarker measures.
Who May Be Eligible (Plain English)
Original Eligibility Criteria
View original clinical language
Treatments Being Tested
Cognitive/Neuropsychological Testing
Comprehensive testing of cognitive function and brain health.
Vestibular/Ocular-Motor Testing
A series of tests and questionnaires that asses vestibular function, balance, ocular-motor coordination, and reflexes.
Sleep Evaluation
A full assessment of sleep health, including insomnia (duration, frequency, daytime consequences) and other sleep disorders such as obstructive sleep apnea. Overnight sleep study is included.
MRI, High-Resolution
A high-resolution MRI to provide qualitative and quantitative assessments of brain structure.
Health & Physical Exam
Participants will undergo an executive history and physical exam of all body systems.
Physical Function
These assessments will involve a series of tests and questionnaires that focus on physical function.
Blood Testing and Biomarker Analysis
A blood draw will be performed to measure standard clinical labs as part of a full history and physical, as well as additional analysis of biomarkers indicative of brain health. An optional lumbar puncture will be performed and CSF samples (20-30 mL) stored in the NCTC Biorepository until shipment to the CLIA-certified laboratory. Both CSF and blood samples will be analyzed for t-tau, p-tau, and Aβ42 and stored for future testing,
Applanation Tonometry
Hearth health is evaluated through testing of arterial stiffness and pulse wave reflections using a high fidelity applanation tonometer.
PET brain imaging
PET imaging of the brain using tau and amyloid ligands.
[C-11]6-OH-BTA-1
PET imaging of the brain using an amyloid ligand.
[F-18]AV-1451
PET imaging of the brain using a tau ligand.